Genflow Biosciences plc
GENF.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | £1 | £1 | £0 | £0 |
| Gross Profit | -£1 | -£1 | -£0 | £0 |
| % Margin | – | – | – | – |
| R&D Expenses | £1,151 | £960 | £724 | £86 |
| G&A Expenses | £1,811 | £1,799 | £499 | £528 |
| SG&A Expenses | £1,908 | £837 | £665 | £667 |
| Sales & Mktg Exp. | £97 | -£961 | £166 | £139 |
| Other Operating Expenses | -£1,153 | £0 | -£55 | £185 |
| Operating Expenses | £1,907 | £1,798 | £1,335 | £938 |
| Operating Income | -£1,267 | -£1,799 | -£1,335 | -£988 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -£320 | £170 | -£0 | -£0 |
| Pre-Tax Income | -£1,587 | -£1,629 | -£1,335 | -£988 |
| Tax Expense | £0 | -£0 | £0 | £0 |
| Net Income | -£1,587 | -£1,629 | -£1,335 | -£988 |
| % Margin | – | – | – | – |
| EPS | -0.005 | -0.006 | -0.005 | -0.003 |
| % Growth | 16.1% | -21.7% | -35.3% | – |
| EPS Diluted | -0.005 | -0.006 | -0.005 | -0.003 |
| Weighted Avg Shares Out | 334,507 | 292,507 | 292,507 | 292,507 |
| Weighted Avg Shares Out Dil | 334,460 | 292,507 | 292,507 | 292,507 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £1 | £1 | £0 | £237 |
| EBITDA | -£1,586 | -£1,798 | -£1,335 | -£988 |
| % Margin | – | – | – | – |